Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsProvidence Medicare Part B Step Therapy Coverage |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentProvidence Health PlanPolicy N/A

    Medicare Part B Step Therapy Criteria for Part B Drugs

    Customize your policy alerts

    Sign up for all Providence Health Plan policy alerts

    Know when Providence Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy requirements, prior authorization expectations, and the list of Part B-administered drugs subject to step therapy for Providence Medicare Advantage Plans members. Affects providers prescribing or administering Medicare Part B drugs to Providence Medicare Advantage enrollees.

    Policy Summary
    PayerProvidence Health Plan
    PolicyMedicare Part B Step Therapy Criteria for Part B Drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewJun 1, 2026
    Next Review DateJun 1, 2026
    Key ActionObtain prior authorization and document why prior steps were ineffective, not tolerated, or prior use within 365 days for Step 2/3 drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~250+Part B medication entries listed
    365Lookback period (days)
    SomeSome Step 1 require PA
    Step 2/3Non-preferred require PA

    Coverage Criteria

    General Step Therapy Criteria

    Covered when step therapy rules are satisfied.

    General Step Therapy Logic: Member must trial preferred Step 1 drug(s) before Step 2 or Step 3 drugs unless an exemption applies.

    Members who received the non-preferred drug in the prior 365 days are exempt; Step 1 drugs may require prior authorization; Step 2 and Step 3 always require prior authorization and clinical justification or documentation of prior use.

    Members who have received the non-preferred Part B drug within the prior 365 days are exempt from step therapy requirements. In other words, if the member has documentation of treatment with the same non-preferred drug during the last 365 days, the member does not need to first trial a preferred (Step 1) agent before receiving the non-preferred (Step 2 or Step 3) drug.

    Coding and Lookback

    Listed Part B HCPCS/Codesmixed
    J3262Actemra (Tocilizumab)
    J0791Adakveo (Crizanlizumab-tmca)
    J7173Alhemo (Concizumab-mtci)
    J1552Alyglo (Immune globulin, gamma(IGG)-stwk)
    Q5126Alymsys (Bevacizumab-maly)
    J1554Asceniv (Immune globulin)
    Q5161Aukelso/Bosaya (denosumab-kyqq)
    J9035Avastin (Bevacizumab)
    J3145Aveed (Testosterone undecanoate)
    Q5121Avsola (Infliximab-axxq)
    1–10 of 138
    1/14
    Policy Summary
    PayerProvidence Health Plan
    PolicyMedicare Part B Step Therapy Criteria for Part B Drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewJun 1, 2026
    Next Review DateJun 1, 2026
    Key ActionObtain prior authorization and document why prior steps were ineffective, not tolerated, or prior use within 365 days for Step 2/3 drugs.
    SourceLink
    On This Page
    Coverage CriteriaCoding and LookbackProvider Actions and AuthorizationBackgroundDefinitionsInitial Therapy CriteriaStep Therapy Table
    Prior use lookback period (inv-04)
    Lookback period365 days — members who received the non-preferred drug within the prior 365 days are exempt from step therapy.
    ScopeApplies to Medicare Part B step therapy for medically administered drugs (injectables, biologics).
    Effect on prior authorizationPrior authorization requirements may still apply to preferred and non-preferred drugs despite the exemption.

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for all Step 2 and Step 3 drugs. Some Step 1 (preferred) drugs may also require prior authorization — check the drug list for exceptions. Your patient’s prescriber must submit a completed prior authorization request before the drug is covered.

    • Step 2 and Step 3 drugs always require prior authorization.
    • Some Step 1 drugs may require prior authorization — see drug-specific list.
    Step Therapy

    Step Therapy Requirement

    Step therapy requires a trial of a Step 1 (preferred) drug before a non-preferred Step 2 or Step 3 drug will be approved. For Step 3 drugs, the member generally must have tried and failed (or have a contraindication/intolerance to) both a Step 1 and a Step 2 drug prior to approval.

    • To obtain a Step 3 drug, the member must first have trialed a Step 1 and a Step 2 drug unless an exemption is documented.
    • Exemptions include documented contraindication or intolerance to required prior steps.
    Documentation Required

    Required Documentation for Prior Authorization

    When requesting prior authorization, the prescriber must document why earlier step(s) were ineffective or not tolerated, or provide evidence of prior use within the last 365 days. Documentation should clearly state the clinical rationale for moving to the requested (non-preferred) drug.

    • For Step 2 requests: document why the Step 1 drug failed or cannot be used, OR why the Step 2 drug is clinically preferred, OR provide evidence of Step 2 use within the past 365 days.
    • For Step 3 requests: document why Step 1 and Step 2 drugs failed or cannot be used, OR why the Step 3 drug is clinically preferred, OR provide evidence of Step 1/Step 2 use within the past 365 days.
    Denial Risk

    Denial Risk for Unmet Step Therapy or PA Requirements

    If step therapy requirements or prior authorization criteria are not met or documentation is incomplete, the request may be denied. Denials typically occur when required trials are not documented, clinical rationale is missing, or supporting records (including recent medication history) are not provided.

    • Incomplete prior authorization forms or missing clinical notes may result in denial.
    • Lack of documentation showing prior trials within the past 365 days risks denial.
    • Requests that do not justify medical necessity relative to required step therapy may be denied.

    Background

    Medicare Part B covers certain physician‑administered injectable and infused drugs and biologics, and some of these medications are subject to step therapy. Step therapy requires a trial of a preferred agent (Step 1) before a non‑preferred agent (Step 2 or Step 3) will be covered, although both preferred and non‑preferred drugs may still require prior authorization or quantity limits. The policy also allows cross‑plan sequences (Part B vs Part D) where coverage of a Part B drug may depend on prior use of a Part D drug or vice versa, depending on the therapy described for the medical condition.

    Definitions

    Step 1 definition (inv-10)
    DefinitionStep 1 = Preferred drug (preferred agent).
    Prior authorizationStep 1 drugs usually require prior authorization; if a specific Step 1 drug does not require prior authorization this will be indicated in the drug list.
    Role in step therapyTrial of a Step 1 agent is required before covering Step 2 or Step 3 drugs unless an exemption applies (e.g., prior use within 365 days or clinical justification).
    Step 2 definition (inv-11)
    DefinitionStep 2 = Non-preferred drug.
    Prior authorizationStep 2 drugs always require prior authorization.
    Documentation requiredProvider must document why the Step 1 drug was ineffective or not tolerated, why the Step 2 drug is clinically necessary, or that the member received the Step 2 drug in the past 365 days.
    Step 3 definition (inv-12)
    DefinitionStep 3 = Non-preferred drug.
    Prior authorizationStep 3 drugs always require prior authorization.
    Documentation requiredProvider must document why Step 1 and Step 2 drugs were ineffective or not tolerated, why the Step 3 drug is clinically necessary, or that the member received the Step 1 and/or Step 2 drug(s) in the past 365 days.

    Initial Therapy Criteria

    Initial Therapy — general initial step therapy rules

    General initial step therapy rules.

    Initial step therapy: Before covering Step 2 or Step 3 drugs, member must have trial of Step 1 preferred drug(s) unless exempted by prior use within 365 days or clinical justification.365 days

    Specific drug-level criteria are linked from the list. For Step 2 and Step 3 drugs providers must submit prior authorization documenting why prior steps were ineffective or not tolerated, or documentation of prior use within the past 365 days. Step 1 drugs usually require prior authorization as indicated in the drug list.

    Step Therapy Table

    StepRequirementPrior AuthorizationDocumentation to Support Exception
    Step 3 (Non-Preferred drug)
    Requires prior trials of Step 1 and Step 2 (where applicable) before coverage unless exempted by prior use within 365 days or clinical justification.
    Always requires prior authorization.
    Provider must document why Step 1 and Step 2 were ineffective or not tolerated, why Step 3 is clinically necessary, or provide records showing prior use of Step 1 and/or Step 2 drugs within the past 365 days.